Drug Profile
APN 431
Alternative Names: APN-431Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Domainex
- Developer Apeiron Biologics; Domainex
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action CBLB protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Solid-tumours in Austria
- 09 Nov 2020 Apeiron Biologics and Domainex agree to co-develop APN 431 for Cancer
- 09 Nov 2020 Preclinical trials in Solid tumours in United Kingdom (unspecified route), prior to November 2020